Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy

Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer R, Utikal JS, Goeppner D, Hassel JC, Meier F, Tietze JK, Thomas I, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling L, Berking C (2016)

Publication Type: Journal article

Publication year: 2016

Journal

Book Volume: 60

Pages Range: 190-209

DOI: 10.1016/j.ejca.2016.02.025

Abstract

Anti-programmed cell death receptor-1 (PD-1) antibodies represent an effective treatment option for metastatic melanoma as well as for other cancer entities. They act via blockade of the PD-1 receptor, an inhibitor of the T-cell effector mechanisms that limit immune responses against tumours. As reported for ipilimumab, the anti-PD-1 antibodies pembrolizumab and nivolumab can induce immune-related adverse events (irAEs). These side-effects affect skin, gastrointestinal tract, liver, endocrine system and other organ systems. Since life-threatening and fatal irAEs have been reported, adequate diagnosis and management are essential.In total, 496 patients with metastatic melanoma from 15 skin cancer centers were treated with pembrolizumab or nivolumab; 242 side-effects were described in 138 patients. In 116 of the 138 patients, side-effects affected the skin, gastrointestinal tract, liver, endocrine, and renal system. Rare side-effects included diabetes mellitus, lichen planus, and pancreas insufficiency due to pancreatitis.Anti-PD1 antibodies can induce a plethora of irAEs. The knowledge of them will allow prompt diagnosis and improve the management resulting in decreased morbidity.

Authors with CRIS profile

Involved external institutions

Universitätsklinikum Tübingen Germany (DE) Universitätsmedizin der Johannes Gutenberg-Universität Mainz Germany (DE) Universitätsspital Zürich (USZ) Switzerland (CH) Universität Duisburg-Essen (UDE) Germany (DE) Technische Universität München (TUM) Germany (DE) Deutsches Krebsforschungszentrum (DKFZ) Germany (DE) Universitätsklinikum Magdeburg A.ö.R. Germany (DE) Universitätsklinikum Heidelberg Germany (DE) Universitätsklinikum Carl Gustav Carus Dresden Germany (DE) Ludwig-Maximilians-Universität (LMU) Germany (DE) Universitätsklinikum Münster Germany (DE) Universitätsklinikum Aachen (UKA) Germany (DE) Universitätsklinikum Würzburg Germany (DE) Medizinische Hochschule Hannover (MHH) / Hannover Medical School Germany (DE)

How to cite

APA:

Hofmann, L., Forschner, A., Loquai, C., Goldinger, S.M., Zimmer, L., Ugurel, S.,... Berking, C. (2016). Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. European Journal of Cancer, 60, 190-209. https://doi.org/10.1016/j.ejca.2016.02.025

MLA:

Hofmann, Lars, et al. "Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy." European Journal of Cancer 60 (2016): 190-209.

BibTeX: Download